ASX:NEU Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Neuren Pharmaceuticals Stock (ASX:NEU) 30 days 90 days 365 days Advanced Chart Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Neuren Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,935 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.Read More… Receive NEU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NEU Stock News HeadlinesNeuren Pharmaceuticals Ltd NURPFDecember 21 at 7:22 PM | morningstar.comNeuren Pharmaceuticals Boosts Buy-Back ProgramDecember 12, 2024 | markets.businessinsider.comSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just months ago. Louis has identified six specific AI stocks that are poised to benefit from this.December 24, 2024 | InvestorPlace (Ad)Neuren Pharmaceuticals Limited's (ASX:NEU) Intrinsic Value Is Potentially 60% Above Its Share PriceDecember 5, 2024 | finance.yahoo.comScott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?November 15, 2024 | msn.comNeuren Pharmaceuticals’ Commitment to Neurodevelopmental CareNovember 15, 2024 | markets.businessinsider.comNeuren Pharmaceuticals Unveils A$50 Million Share Buy-BackNovember 14, 2024 | markets.businessinsider.comBuy this ASX 200 share that is swimming in cashNovember 12, 2024 | msn.comSee More Headlines NEU Stock Analysis - Frequently Asked Questions How were Neuren Pharmaceuticals' earnings last quarter? Neuren Pharmaceuticals Limited (ASX:NEU) issued its quarterly earnings data on Wednesday, February, 27th. The company reported $0.03 earnings per share for the quarter. Neuren Pharmaceuticals had a net margin of 60.66% and a trailing twelve-month return on equity of 75.51%. What other stocks do shareholders of Neuren Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuren Pharmaceuticals investors own include Oxford Lane Capital (OXLC), Pilbara Minerals (PLS), Sunrise Energy Metals (SRL), Westpac Banking (WBC), FBR (FBR), Embark Early Education (EVO) and Dream Industrial Real Estate Investment Trust (DREUF). Company Calendar Last Earnings2/27/2019Today12/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryChemicals Current SymbolASX:NEU CUSIPN/A CIKN/A Webwww.neurenpharma.com Phone61 3 9092 0480FaxN/AEmployees2,060Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.93 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$117.29 million Net Margins60.66% Pretax MarginN/A Return on Equity75.51% Return on Assets59.56% Debt Debt-to-Equity RatioN/A Current Ratio25.42 Quick Ratio31.54 Sales & Book Value Annual Sales$193.34 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.46 Book ValueA$1.72 per share Price / BookN/AMiscellaneous Outstanding Shares130,070,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta2.13 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (ASX:NEU) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuren Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.